{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-032145","form_type":"8-K","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.324108+00:00","generated_at":"2026-06-21T21:40:03.805014+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sanara MedTech Q3 revenues surge 124% to $13M; net loss narrows to $1.5M","bullets":["Q3 revenue $13.0M (up 124% YoY); nine-month revenue $30.5M (up 78%); includes $3.0M from Scendia acquisition.","Gross margin 87% for nine months, down from 91% due to lower margins on Scendia products.","SG&A $12.1M (+75%); R&D $1.1M (vs $0.04M a year ago) driven by Precision Healing and new development projects.","Net loss improved to $1.5M from $2.0M on $1.7M non-cash tax benefit; nine-month net loss $3.9M vs $4.4M.","Operational: record monthly revenue >$4M; post-quarter partnership with InfuSystem; FDA 510(k) submission for BIASURGE."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-032145","json":"https://secwatch.observer/filing/0001493152-22-032145.json","markdown":"https://secwatch.observer/filing/0001493152-22-032145.md","text":"https://secwatch.observer/filing/0001493152-22-032145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000149315222032145/0001493152-22-032145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000149315222032145/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:40:03.805014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"872411b9f278d35de1de63ebd2d040ce920627a9","claim":"Sanara MedTech Inc. reported the quarter ended September 30, 2022 results: revenue $13.0 million.","evidence_excerpt":"For the three months ended September 30, 2022, the Company generated net revenues of $13.0 million compared to net revenues of $5.8 million for the three months ended September 30, 2021 representing a 124% increase from the prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/714256/000149315222032145/0001493152-22-032145-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$13.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}